GlaxoSmithKline paid $184 million to settle claims by 8 states (Kentucky, Louisiana, Maryland, Mississippi, New Mexico, South Carolina, West Virginia, and Utah) that the company illegally promoted the Avandia diabetes drug. The settlement resolved claims that GSK misled consumers about Avandia’s cardiovascular risks. The settlement also resolved allegations brought by Louisiana involving other Glaxo prescription drugs, which Glaxo agreed to settle for $45 million (see GlaxoSmithKline instance, “Louisiana Off-Label Marketing Lawsuit”). The total settlement was for $229 million and the company did not admit to any wrongdoing or liability. See related GlaxoSmithKline instance, “Multistate Avandia Settlement (November 2012)”.